



Insights Into Myelofibrosis (MF)

Date: November 9th, 2022

Chair: Abdulraheem Yacoub, MD

AGENDA

Time (CT)	Topic
6.00 PM – 6.15 PM (15 min)	Introduction <ul style="list-style-type: none"> Program overview
6.15 PM – 7.00 PM (25-min presentation; 20-min discussion)	Current Management and Challenges in MF <ul style="list-style-type: none"> ARS questions Diagnosis and workup <ul style="list-style-type: none"> Risk assessment and stratification Prognostic genetic mutations Symptom burden assessment/monitoring for signs of disease progression to symptomatic disease Current therapy paradigms for MF <ul style="list-style-type: none"> Ruxolitinib prognosis and dosing Proliferative MF Cytopenic MF Impact of platelet counts and anemia/transfusion dependency on therapy, prognosis, and quality of life Dosing of current therapy approaches and unmet needs On-treatment prognostic factors: splenomegaly, thrombocytopenia (disease and treatment related), anemia, and transfusion dependency Moderated discussion
7.00 PM – 7.45 PM (15-min presentation; 30-min discussion)	Unmet Needs and Emerging Paradigms <ul style="list-style-type: none"> ARS questions Unmet needs and emerging paradigms <ul style="list-style-type: none"> New and emerging pathways: <i>JAK2</i> V617F variable allelic frequency burden and the disease course Recent approvals in MF with targets beyond JAK/STAT (eg, pacritinib; JAK1-sparing select inhibitor of JAK2/IRAK) Future directions Moderated discussion
7.45 PM – 8.00 PM (15 min)	Key Takeaways and Meeting Evaluation